RGCC Testing Through CIOFM
RGCC (Research Genetic Cancer Centre) is a global leader in personalized cancer diagnostics and treatment. Established in 2004, RGCC focuses on using innovative technologies to advance the early detection, analysis, and monitoring of cancer. Their cutting-edge tests, developed in state-of-the-art laboratories worldwide, analyze a patient's genetic, molecular, and cellular profiles. This approach enables the creation of highly personalized treatment plans that are tailored to the specific characteristics of each individual's cancer.
Dr. Jamie is now certified to offer RGCC testing, bringing this state-of-the-art technology to her patients. Her certification and extensive experience in integrative oncology allow her to interpret the results and integrate them into personalized treatment plans that combine conventional and natural therapies.
Featured RGCC Tests
Onconomics Plus
Onconomics Plus is ideal for those seeking to optimize their cancer treatment through personalized therapy. By analyzing how your cancer cells respond to various anti-cancer drugs, targeted therapies, and natural treatments, Dr. Jamie can craft a treatment plan that maximizes effectiveness.
This test is especially valuable for:
Patients actively undergoing cancer treatment who need tailored therapy options.
Those exploring integrative approaches alongside conventional treatments.
Individuals looking for precise insights into their cancer's drug sensitivity.
How Onconomics Plus Works
The test requires a blood or tissue sample, which is analyzed to determine the efficacy of various treatments. Results are typically available within 7-10 days, offering a detailed guide to personalized cancer therapy.
Oncotrace
Oncotrace RGCC is a crucial test for closely monitoring cancer, especially for tracking disease progression and treatment response. By detecting circulating tumor cells (CTCs) in the bloodstream, Dr. Jamie can gauge how effectively your current treatment is working and make timely adjustments.
This test is particularly beneficial for:
Patients with an existing cancer diagnosis who need to monitor treatment efficacy.
Individuals at high risk for metastasis requiring vigilant monitoring.
Those seeking detailed insights into their cancer's behavior over time.
How Oncotrace RGCC Works
The Oncotrace RGCC test involves a straightforward blood draw to identify and quantify CTCs. Results are typically available within 7-10 days, providing a detailed analysis that helps tailor ongoing treatment plans and monitor cancer's activity.
Onco-D-clare
This test allows for early detection of cancer cells on a blood test which then segues into a work-up of the source of cancer, leading potentially to a very early diagnosis and treatment.
Onco-D-clare is a helpful test for:
Individuals with a family history of cancer or those with genetic predispositions.
Anyone looking to take a proactive approach to cancer prevention and early detection.
How Onco-D-clare Works
The Onco-D-clare test involves a simple blood draw, requiring only 5-8 ml of peripheral blood. This sample is analyzed to identify specific gene expression profiles associated with cancer. The results, available within 7-10 days, provide a comprehensive analysis that distinguishes between healthy and cancerous samples.